The current study investigated the mediating role of phosphodiesterase type 4 (PDE4) regulated cAMP in the dopaminergic modulation of premature responding (action restraint) in rats. Response inhibition, which includes action restraint, finds its neurobiological origin in cortico-striatal-thalamic circuitry and can be modulated by dopamine. Intracellularly, the effect of dopamine is largely mediated through the cAMP/PKA signaling cascade. Areas in the prefrontal cortex are very sensitive to their neurochemical environment, including catecholamine levels. As a result, we investigated the effects of intracellular modulation of the dopamine cascade by means of PDE4 inhibition by roflumilast on premature responding in a hypo, normal and hyper dopaminergic state of the brain. As a hypo dopaminergic model we induced a 6-OHDA lesion in the (rat) prefrontal cortex, more specifically the infralimbic cortex. For the hyper dopaminergic state we also turned to a well-established model of impaired action restraint, namely the systemic administration of d-amphetamine. In line with the notion of a Ushaped relation between dopamine and impulsive responding, we found that both increasing and decreasing dopamine levels resulted in an increase in premature responding in the choice serial reaction time task (CSRTT). The PDE4 inhibitor roflumilast increased premature responses in combination with d-amphetamine, whereas a decrease in premature responding after roflumilast treatment was found in the 6-OHDA lesioned animals. As a result, it would be interesting to test the effects of PDE4 inhibition in disorders affected by disrupted impulse control related to cortico-striatal-thalamic hypodopaminergia including attention deficit hyperactivity disorder (ADHD).
Introduction
Controlling impulsivity is of vital importance for daily decision making. A lack of control over impulsive responses can have severe consequences and is considered a key feature of various psychiatric disorders [1] . Examples of these disorders are: addiction, bipolar disorder, attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), eating disorders and gambling disorder [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Impulsivity is a multifaceted concept, which, in daily life, can appear in many different forms [21] [22] [23] . To make this multifaceted concept easier to study, impulsivity is generally divided into impulsive actions, i.e. an inability to inhibit a response, and impulsive choices, i.e. a distorted judgment with respect to choosing between two differential reward outcomes. A third main type of impulsivity is reflection impulsivity, i.e. making decisions before adequately sampling and evaluating available information. However, splitting the behavioral construct into six subcategories is perhaps more appropriate. Within impulsive actions there is a clear distinction between action restraint (inhibiting a prepotent, inappropriate response) and action cancellation, i.e. response inhibition or volitional control over responding once the response has been initiated. Impulsive choice may be subdivided into delay-, uncertainty-, and effortbased decision making. Impulsivity is a critical component of psychiatric symptoms within the class of 'inhibition' and is separated from compulsivity, perseveration, disinhibition, obsession, aggression, attention and mania [2] .
Current knowledge on the human neuroanatomical substrate of impulse control points to the cortico-striatal-thalamic circuits [24] [25] [26] . The cortico-striatal-thalamic circuits comprise a complex mechanism of action and functionality, which is abundantly described elsewhere (e.g [27] [28] [29] [30] [31] [32] .). The different subtypes of impulsivity arise from the dysfunction of different fundamental anatomical and neurochemical mechanisms within the cortico-striatal-thalamic circuitry. Although the general anatomical organization related to impulse control is known, the delicate control of neurotransmitter balance in these circuits and its effects on brain functioning and behavior are not yet fully understood. Studies using different drugs that interfere with this neurotransmitter balance have increased our understanding of the neurobiological regulation of impulse control (e.g [33] [34] [35] [36] .).
One of the key neurotransmitter systems involved in cortico-striatal physiology is the dopaminergic system, originating in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) [29] . It is well accepted that dopamine plays an important regulatory role in many forms of impulsivity, especially impulsive action, as is supported by a wealth of preclinical and clinical studies (for a review see e.g [26, [33] [34] [35] [36] [37] [38] .). Psychostimulants, as amphetamine, acting on dopamine (among other monoamines) in the dorsal striatum, nucleus accumbens, subthalamic nucleus and prefrontal areas, have opposing roles in both types of impulsive action as they improve performance on the stopsignal task (SST; action cancellation) as shown in both healthy rats and humans [39] [40] [41] , but impair performance on the choice serial reaction time task (CSRTT; action restraint) in rats [42] and continious performance task in humans [43] .
Intracellularly, the effect of dopamine is largely mediated through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling cascade [44] [45] [46] [47] [48] [49] [50] [51] . This cascade is thus a potential target for pharmacological intervention in several types of impulsivity-related disorders, including ADHD and addiction. Via this cascade the regulatory effect of dopamine on impulsivity can be modulated. The most prominent mean to target cAMP is via specific cyclic nucleotide phosphodiesterases (PDEs) [52, 53] . Especially, the PDE4 subfamily is involved in the regulation of striatal dopaminergic cAMP/PKA signaling [44, 54, 55] . For instance, within the striatum, the synthesis of dopamine by tyrosine hydroxylase (TH) [56, 57] and the release of dopamine from nigrostriatal dopaminergic terminals [58] [59] [60] are both regulated by the cAMP/PKA signaling cascade, which, in turn, can be modulated by inhibitors of the PDE4 subfamily [48] . Also, cAMP stimulation counteracts D2 receptor activation in the striatum [45, 46, 48, 51] . Additionally, PDE4 inhibitors modulate dopamine D1-receptor signaling in the frontal cortex, as D1 receptors are G s -coupled which, in turn, stimulate cAMP [47] .
Based on the above, we were interested in the effects of PDE4 inhibition on action restraint as measured by premature responding in a hypo, normal and hyper dopaminergic state of the brain. As a hypo dopaminergic model we induced a 6-hydroxy dopamine (6-OHDA) lesion in the medial prefrontal cortex of rats, more specifically the infralimbic cortex. This is a well-known animal model for the induction of motor impulsivity related to action restraint in for instance ADHD [61, 62] . It has been suggested that the proper functioning of the areas in the prefrontal cortex is very sensitive to optimal levels of catecholamines [63] . High, as well as, low catecholamine release can impair prefrontal cortex functioning. For the hyperdopaminergic state we also turned to a well-established model of impaired action restraint, namely the systemic administration of d-amphetamine, which has proven to robustly increase premature responding [23] . Taken together, we investigated the effects of the, for human administration approved, PDE4 inhibitor roflumilast on premature responding in the CSRTT in a hypo, normal and hyper dopaminergic state of the rat brain. The main aim of the current study was to evaluate if roflumilast is able to normalize the motor impulsivity deficits induced by hypo or hyper dopaminergic functioning (pathological conditions), as well as to investigate the effects in a normal physiological condition of the cortico-striatal-thalamic circuitry. Based on the role of PDE4 in dopamine release, we hypothesized that roflumilast changes motor impulsivity deficits induced by hypo and hyper dopaminergic functioning (6-OHDA lesion and damphetamine, respectively).
Materials and methods

Animals
All experimental procedures were approved by the local ethical committee for animal experiments of Maastricht University and met governmental guidelines. Sixty 3-month-old male Wistar rats (Charles River, The Netherlands) were used in three separate studies (20 animals per study; within-subject design), with average body weights of 386 g ( ± 11.66). The animals were housed in pairs in standard Makrolon cages on sawdust bedding in an air-conditioned room (about 20°C). They were kept on a 12/12-h reversed light/dark cycle (lights on from 19:00 h to 7:00 h). The rats were housed in the same room as where they were tested. A radio, which was playing softly, provided background noise in the room. All testing was done between 9:00 h and 18:00 h in a shielded Skinnerbox. Animals had free access to water, but limited food access to reduce their body weight to 85-90 % of their free feeding weight.
Apparatus
The rats were tested in ten identical operant chambers (inner dimensions: 40 × 30 x 33 cm), which were equipped with two retractable levers and cue lights just above the levers. A food tray (5 x 5 cm and 2.5 cm above the grid floor), which was positioned equidistant between the two levers, could be accessed by pushing a hinged panel. The levers (4 cm wide) projected 2 cm into the conditioning chamber and were located 6 cm from each side of the food tray and 12 cm above the grid floor. A house light and a loudspeaker were fixed in the ceiling of the conditioning chamber. The operanda and manipulanda in the chambers were controlled by a personal computer and the data were stored at the end of a session.
Experimental procedures
Magazine (MG) and continuous reinforcement training (CRF)
Behavioral training started with magazine (MG) training (30 min sessions) in which the rats had to learn to push back the hinged panel in order to obtain a food reward (45 mg sucrose pellets). The next stage of training consisted of continuous reinforcement training (CRF), in which either the left or right lever was inserted in the conditioning chamber after a rat had pressed the hinged panel of the food tray. Whenever a lever was inserted into the chamber the cue light above the lever was switched on. A food reward was provided when a rat had pressed the lever.
Fixed ratio 5 schedule of reward
Next the rats were trained on a fixed ratio schedule of reinforcement, in which they had to press a lever for five times (FR5) in order to obtain a 45 mg food reward. Reinforcement was continuous; i.e. each set of five lever presses was rewarded. A session was terminated after 60 trials or 30 min, whichever applied first. Rats were trained once a day, Monday to Friday, and were given eight FR5 sessions before drug testing started. The measure used to evaluate performance on the FR5 schedule was interresponse time (i.e. time between consecutive lever presses which was averaged for each animal). The purpose of this task was to control for possible effects of any of the pharmacological manipulations used on sensorimotor functioning.
Progressive ratio 10 schedule of reward
After finishing drug testing in the FR5 task, rats immediately started training on a progressive ratio (PR10) schedule of reinforcement. The rats had to progressively increase the response requirement (steps of ten lever presses) to obtain a food reward. For the first food pellet they were required to press ten times, for the next reinforcement they had to press the lever twenty times, and so on. A session was terminated if a rat did not press the lever for 3 min. Rats were trained once a day, Monday to Friday, and were given eight PR10 sessions before drug testing started. The measure used to evaluate performance in the PR10 task was the breakpoint (i.e., total number of lever presses made during a session). The purpose of this task was to control for possible effects of any of the pharmacological manipulations used on food motivation. Fig. 1 
Choice serial reaction time task (CSRTT;
)
Subsequently, rats performed the CSRTT to investigate premature responding [64] . In the CSRTT rats had to push the panel for a longer duration until one of the levers was made accessible. First, a randomly chosen duration of 0.5-1.0 s (steps of 0.1 s) was used. This variable period was called the hold duration. Also, an auditory stimulus was presented when the hold duration had elapsed. A high tone (10 kHz; 80 dB) predicted insertion of the left lever, and a low tone (2.5 kHz; 80 dB) predicted the insertion of the right lever. The insertion of the lever took about 2 s. This tone was turned off when the rat withdrew its nose from the food tray. When a rat did not succeed in pressing the panel for the entire hold duration (premature response), the same interval was started again upon pressing the panel. After the rats showed a steady performance during this stage, they were required to push the panel for a randomly chosen duration of 0.5-1.5 s (steps of 0.1 s). These hold durations were used during all further testing. The inter-trial interval was 10 s A session lasted 30 min or until a rat had completed 60 trials. After the rats showed a stable performance, i.e. equivalent amount of premature responses per trial and stable performance on the measure reaction time on five successive sessions, which occurred after about 2 weeks of training in this task, the rats were subjected to the main test paradigm (pharmacological manipulations).
The following parameters were used to evaluate the responding of the rats.
Reaction time (RT): the main latency between the onset of the tone and the release of the hinged food tray panel (after pushing it away). It is generally accepted that response latencies shorter than 100 ms may not reflect true RT [65] . These latencies were counted as premature responses. Response latencies longer than 1500 ms were not considered to be task-related RTs and were excluded from the dataset.
Motor time (MT): the mean latency between the release of the hinged food tray panel and the lever press. It was assumed that MT of more than 2 s do not reflect true MT [65] .
Number of trials: the total number of trials the rats completed in a session of maximum 30 min.
Premature responses (PR): the total number of times that the rat released the hinged panel before the hold duration had elapsed. In the present study, we always used the ratio of PR (i.e. the PR divided by the total number of trials (correct + incorrect + premature). Furthermore, a PR caused the trial to start over again.
Pharmacological manipulations
The PDE4 inhibitor roflumilast (kindly donated by Takeda, Konstanz, Germany) was tested in the FR5, PR10 and CSRTT. Roflumilast was freshly dissolved on each day of testing. Drug administration of the PDE inhibitor occurred 30 min prior to behavioral testing for all three paradigms (FR5, PR10 and CSRTT), in all three studies (hypo, hyper and normal dopaminergic state of the corticostriatal-thalamic circuitry) using a Latin square design. Roflumilast was administered intraperitoneally (i.p.) in doses of 0.001, 0.003, 0.01, 0.03 and 0.1 mg/kg. Roflumilast was first dissolved in 1.0 ml 100% ethanol with 2% Tween 80. After extraction of ethanol via vaporization under N 2 gas, the compound was dissolved in 0.5% methylcellulose. Roflumilast was administered in a volume of 1 ml/kg. In the second study, the hyper dopaminergic state was induced by acute administration of d-amphetamine (Sigma Aldrich, Zwijndrecht, The Netherlands). d-Amphetamine was administered i.p. 30 min before behavioral testing started (1.0 mg/kg) in an injection volume of 1 ml/ kg. d-Amphetamine was dissolved in 0.9% saline. Roflumilast and damphetamine were not administered during training. In the third study, a hypo dopaminergic state was induced in the infralimbic cortex as explained below. In all three studies every animal received every dose of roflumilast (within-subjects design). Dosages, injection volumes and time of injection are based on extensive previous experience of the lab with the current drugs.
Stereotactic surgery (study 3; 6-OHDA lesions)
In the third study, the effects of the PDE4 inhibitor roflumilast were tested in a hypo dopaminergic state of the infralimbic cortex. The hypo dopaminergic state was induced by means of a 6-hydroxydopamine (6-OHDA) lesion. The animals received stereotactic injections of 2 μl 6-OHDA (n = 10; 5 μg/μl dissolved in 0.9% saline and 0.2% ascorbic acid; Sigma Aldrich, Zwijndrecht, The Netherlands) or the same injection amount of the vehicle solution (n = 10; 0.9% saline and 0.2% ascorbic acid) at four sites (two per hemisphere) in the infralimbic cortex. One hour before the surgery, rats received desipramine (30 mg/kg in 0.9% saline, injection volume 1 mg/kg; i.p.). Desipramine was administered to protect noradrenergic neurons from possible damage by 6-OHDA and thus make the lesion more dopamine specific [66] . The animals were anaesthetized using isoflurane (induction 5%, maintenance 2%) and subsequently placed in a stereotactic frame. Surgery site was pretreated with lidocaine for local anesthesia. Corneal dehydration was prevented by applications of Vaseline. Body temperature was maintained at 37 ± 0.5°C using a homeothermic heating blanket (Harvard Apparatus, Kent, UK). The injections of 6-OHDA or vehicle were performed in the infralimbic cortex at the following coordinates [67] : AP: + 3.2 mm, L: 0.6 and -0.6 mm, and DV: −4.8 and −5.4 mm (from bregma). Injection speed was 0.5 μl/min and the cannula was left in place for an additional 2 min before slowly retracting it. Pre-operatively and 8 h post-operatively, Temgesic (0.05 mg/kg) was administered subcutaneous as analgesic. The animals were put back in their home cages for recovery, and weighted and handled daily. The animals had free access to food and water after surgery. Food and water was consumed without problems. As is customary in impulsivity research [68] [69] [70] , the 50% most impulsive animals (upper halve of total group based on performance) out of 10 animals were selected to proceed to drug testing. In the sham group all animals proceeded to drug testing. 
Statistics
Statistical analysis was carried out using IBM SPSS Statistics 24 software (IBM, Portsmouth, UK). The raw data were checked for outliers using SPSS descriptive statistics and checked for normality of distribution. Paired samples t-test, GLM univariate analysis of variance (ANOVA) as well as GLM one-way repeated measures ANOVA followed by Sidak's post-hoc tests were used. For the paired samples t-test equal variances were assumed unless the Levene's test for equality of variances was significant. P-values were corrected for multiple testing. Data are depicted as means ± SEM.
Results
Fixed ratio 5 schedule of reward
All animals completed the 60 trials within 30 min. Roflumilast, damphetamine and the infralimbic cortex 6-OHDA lesion did not affect the inter-response time in the FR5 schedule of reward (data not shown).
Progressive ratio 10 schedule of reward
All animals reached their breakpoint within 30 min. Roflumilast, damphetamine and the infralimbic cortex 6-OHDA lesion did not affect the breakpoint in the progressive ratio 10 schedule of reward (data not shown).
Choice serial reaction time task
Reaction times
For the hypo dopaminergic state, the mixed model ANOVA showed no significant dose x lesion interaction effect (F(3,55) = 0.434, N.S.). Also, there was no main effect of dose (F(3,55) = 0.751, N.S.) or lesion (F(1,55) = 0.259, N.S.) (see Fig. 2 upper panel) . There was no significant effect of roflumilast on the reaction times in a normal dopaminergic state (F(3,27) = 0.632, N.S.; see Fig. 2 middle panel) . Surprisingly, in the hyper dopaminergic state, treatment with damphetamine only showed a trend toward significance to affect the reaction times (t(19) = 1.813; p = 0.08) (see Fig. 2 lower panel) . Roflumilast did not show any effect on the reaction times (F (4,76) = 0.875, N.S.; see Fig. 2 lower panel) .
Motor times
Roflumilast, d-amphetamine and the infralimbic cortex 6-OHDA lesion did not affect the motor times in the CSRTT (data not shown).
Premature responses
For the hypo dopaminergic state, the mixed model ANOVA showed no significant treatment x lesion interaction effect (F(3,48) = 1.289, N.S.). Also, there was no main effect of treatment (F(3,48) = 0.367, N.S.). However, there was a significant main effect of lesion (sham vs. 6-OHDA (high responders); F(1,48) = 18.526, p < 0.001; see Fig. 3 upper panel). Of note, there was no significant lesion effect when comparing sham vs. 6-OHDA for low responders (F(1,49) = 3.091, N.S.). Subsequently, we checked for differences between sham and 6-OHDA lesion per dose of roflumilast. For the 0.01 mg/kg (t (13) = 2.384; p < 0.05) and 0.1 mg/kg (t(4.261) = 3.944; p < 0.05) dosages the 6-OHDA lesioned animals showed significantly higher percentages of premature responses (see Fig. 3 upper panel; Sidak correction for multiple testing). Treatment with 0.03 mg/kg of roflumilast normalized the premature responding of the 6-OHDA lesioned animals to the level of sham lesioned animals (t(13) = 0.586; N.S.).
There was no significant effect of roflumilast on the percentage of premature responses in a normal dopaminergic state (F(3,27) = 0.723, N.S.; see Fig. 3 middle panel) .
In the hyper dopaminergic state, treatment with d-amphetamine increased the percentage of premature responses (t(18)=−4.748; p < 0.01). Subsequent treatment with roflumilast further increased the percentage of premature responses as indicated by the overall treatment effect (F(4,76) = 3.370, p < 0.01; see Fig. 3 lower panel) . Post-hoc analyses revealed a significant increase in premature responding at the 0.01 mg/kg dose compared to d-amphetamine alone ( Fig. 3 lower panel; p < 0.01).
Discussion
The aim of the current study was to investigate the effects of PDE4 inhibition on premature responding in the CSRTT in a hypo, normal and hyper dopaminergic state in rats (infralimbic cortex 6-OHDA lesion, no treatment and d-amphetamine, respectively). Premature responding was used as a measure for action restraint, one of the two types of impulsive action. As expected, 6-OHDA and d-amphetamine increased premature responding in the rats. The PDE4 inhibitor roflumilast increased premature responses in combination with d-amphetamine, whereas a decrease in premature responding after roflumilast treatment was found in the 6-OHDA lesioned animals. In line with the notion of a U-shaped relation between dopamine and impulsive responding [63] , we found that both increasing and decreasing dopamine levels resulted in an increase in premature responding in the CSRTT.
The differential effect of PDE4 inhibition in both dopaminergic models could be explained on the basis of the effects of PDE4 inhibition on dopamine release. The release of dopamine from dopaminergic terminals is influenced by the cAMP signaling cascade which, in turn, is stimulated by inhibitors of the PDE4 subfamily [48, 58] . Therefore, in the hypo dopaminergic state of the cortico-striatal-thalamic circuit, the PDE4 inhibitor roflumilast was expected to increase the release of dopamine, thereby restoring low levels of dopamine to their optimal level. As a result, roflumilast was hypothesized to compensate for the loss in impulse control. Linked to this assumption, treating the 6-OHDA lesioned animals with roflumilast indeed restored the level of premature responding back to the level of the sham-lesioned animals. Additionally, according to hypothesis, roflumilast further increased the already heightened level of premature responding in the hyper dopaminergic state of the cortico-striatal-thalamic circuit, induced by damphetamine. Thus, we again observed a shift to the right on the Ushaped dose-response curve. However, in the normal (untreated) dopaminergic state, roflumilast did not exhibit any effects on the level of premature responding. Based on the results of the current study, roflumilast thus seems to follow our hypothesis based on the dopaminergic dose-response curve except for the non-modulated dopaminergic condition. Possibly due to its effects on dopamine release, roflumilast seems to enhance the effects of dopamine (as was shown before by [51, 58] ), restoring depleted levels and further enhancing already heightened levels of dopamine. As a result, it would be interesting to test the effects of PDE4 inhibition in disorders characterized by impaired action restraint related to cortico-striatal-thalamic hypodopaminergia like ADHD. It was first checked whether the different treatments (i.e. d-amphetamine, infralimbic cortex 6-OHDA lesions, roflumilast) had an effect on sensorimotor functioning (FR5) and food motivation (PR10). None of the treatments showed any effect on these basic response measures in the operant chamber. Therefore, treatment effects in the CSRTT cannot be explained by differences in lever press responding or food motivation, making the effects specific for premature responding. This is in line with previous findings by our group [64, 71] . It also provides support for the hypothesis that 6-OHDA as well as d-amphetamine could be a suitable tool to induce models of dopamine-related motor impulsivity [36, 61, 62] . However, future studies will have to verify our results on a biochemical and electrophysiological level.
Although these data support a relation between dopamine and premature responding, we observed no effects of roflumilast on premature responding in the normal dopaminergic state of the corticostriatal-thalamic circuit. This could be explained by the fact that the brain has a higher level of compensatory ability when catecholamine levels are at an optimum (or near optimum) level. On the other hand, it could also be that, since roflumilast affects the release of dopamine, the effects of roflumilast are most easily observed in experimental conditions in which a dopaminergic challenge is present (6-OHDA or d-amphetamine). It could also be argued that the trough of the U-shaped curve is rather wide, which would reflect the compensatory mechanisms of the organism in physiological conditions. Thus, although roflumilast changed the dopamine levels, the behavioral output remained unchanged [45, 46] . Our data suggest that PDE4 inhibition only has an effect in pathophysiological conditions, when performance lies outside this compensatory window. For the hyper dopaminergic state, it should be noted that d-amphetamine principally targets the transporters for all monoamines and PDE4 is a relatively ubiquitous enzyme playing a role in all cAMP-related signal transduction and therefore the observed relationship cannot irrefutably be attributed to dopamine. Similarly, for the hypo dopaminergic state, it must be mentioned that decreased dopaminergic tone in the prefrontal cortex can have more wide-ranging effects on executive functioning, beyond impulsivity.
Furthermore, there are several methodological considerations when interpreting current results. The CSRTT used in the current studies differs from the traditional 5-CSRTT in the way that no distinction can be made between errors of omission and errors of commission. As a result, some responses, however low in number, might have been incorrectly labeled as premature response. Another point is related to the low number of animals included in the 6-OHDA condition. As is customary in impulsivity research, we divided the impulsivity group in high and low responders (e.g. [68] [69] [70] ,). The 50% most impulsive animals (high responders as based on performance) out of the ten 6-OHDA animals were selected to proceed to drug testing. This resulted in a relatively low number of animals. However, the procedure is common and also the 6-OHDA model seems to be effective like in previous studies (e.g. [61, 62] ,). Nevertheless, future studies should replicate our findings using larger sample sizes for the 6-OHDA condition. Also, in the hypo dopaminergic condition there is no treatment effect while we checked for differences between sham and 6-OHDA lesion per dose of roflumilast.
Pharmacokinetics of roflumilast have been established in previous studies by our group [72] and others [73] showing that roflumilast is brain penetrant and cognitively active. Despite brain penetration, a point of attention remains that expression levels of the target of roflumilast, i.e. PDE4 itself, in the infralimbic cortex are currently unknown as are the expression levels at other key structures within the cortico-striatal-thalamic circuitry, e.g., nigral and pallidal areas or the subthalamic nucleus [45, 46] .
To our knowledge, the only other study investigating the effects of a PDE inhibitor on impulsivity is a study recently published using the PDE10 inhibitor TAK-063 [74] . Based on the almost exclusive expression of PDE10 in the striatum [75] and the preferential expression in the indirect dopamine D2 pathway, we hypothesize that a PDE10 inhibitor does the opposite of a PDE4 inhibitor and should shift performance in the CSRTT to the left on the U-shaped dose-response curve. In contrast to this hypothesis, the PDE10 inhibitor TAK-063 showed positive effects in healthy animals. However, it should be noted that, as explained above, not all healthy subjects perform exactly at an optimal level on the U-shaped dose response curve and that the optimum of the curve should be considered rather wide. If a batch of animals or group of participants performs slightly right from the optimal performance on the U-shaped dose response curve, a shift to the left side may be beneficial. Therefore, it would be interesting to add next to a PDE4 inhibitor, a PDE10 inhibitor or PDE1 inhibitor, as PDE10 and PDE1 are also highly expressed in the cortico-striatal-thalamic brain areas, as reference compounds in future studies. This will provide a more complete picture, especially when testing healthy animals.
Taken together, the current study tested a model of dopaminergic modulation in relation to premature responding. In addition, the mediating role of PDE4 inhibition in a hypo, normal and hyper dopaminergic state of the cortico-striatal-thalamic circuitry was investigated. The results of the current study provide a first indication that PDE4 inhibitors could shift performance on premature responding to the right on the U-shaped dose response curve. As a result, it would be interesting to verify these findings on a biochemical and electrophysiological level and test the effects of PDE4 inhibition in models of disorders affected by disrupted impulse control related to corticostriatal-thalamic hypodopaminergia like ADHD.
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